New Jersey Rx Form To Beat Fraud

30 September 1997

New Jersey is launching a new prescription form to protect against theblack market in fraudulent prescriptions, which costs Medicaid and other programs $1 billion a year. After a three-month phase-in period (the start date is yet to be set) these will become the only forms which pharmacies will accept.

The forms are numbered and bound like a checkbook, and cannot be photocopied or erased. Doctors will be required to notify the state within 72 hours if they are stolen; the state will then tell pharmacists in the same way that credit card companies tell merchants about stolen cards.

The program is the first to deal with the totality of the problem, and applies to all prescriptions written by every prescriber. Doctors will still be able to phone in their prescriptions as long as they give their identification numbers when they call.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight